Michelle Nyman, Deputy Vice President for Alliances & Public Affairs at the Pharmaceutical Research & Manufacturers of America (PhRMA), has expressed concerns regarding the pricing of prescriptions at 340B hospitals. "Patients pay far more for prescriptions at 340B hospitals," she said, urging Congress to address the issue. The statement was made on X.
"Patients pay 200% more for prescriptions at 340B hospitals than at non-340B hospitals," said Nyman, Deputy Vice President, Alliances & Public Affairs. "It's time for Congress to fix the 340B Drug Pricing Program."
The 340B Drug Pricing Program, established by Congress in 1992 and administered by the Health Resources and Services Administration (HRSA), allows eligible healthcare providers to purchase outpatient drugs at significantly reduced prices. These savings are intended to help hospitals extend limited federal resources with the aim of improving access to care for low-income and uninsured patients.
According to a 2024 report by the National Alliance of Healthcare Purchaser Coalitions, prices at large 340B hospitals were found to be 35% higher for common outpatient services compared to non-340B hospitals. This pricing gap is estimated to contribute an additional $36 billion annually in healthcare costs for employers. The findings were based on commercial claims data from over 25 million American workers and their families.
A study conducted in 2023 by the Berkeley Research Group revealed that while 340B hospitals comprised 45% of all acute care hospitals, they accounted for nearly 60% of total hospital drug reimbursement. The report indicated that drug reimbursement per patient at these hospitals was nearly double that of non-340B hospitals. The analysis relied on Medicare and commercial claims data.
Nyman leads engagement with health stakeholders at PhRMA to promote access, innovation, and public policy reforms. Her professional background includes strategic roles in advocacy, health communications, and biopharmaceutical policy.
